Leqembi, which was approved in 2023 to treat the mind-robbing disease, generated $168 million in sales, up 74 percent from ...
Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug ...
Join RAPS Boston for an in-person Executive Chat with Diane Rocco, SVP of Global Regulatory Affairs at Biogen, moderated by Ami Mehr. The discussion will explore how regulatory leadership shapes key ...
Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.
Eleanor Nkera during her final internship poster presentation at Biogen. From the Boston Business Journal. Eleanor Nkera grew up in Medford, Massachusetts, a stone’s throw away from the life sciences ...
When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in that area, it serves as strong validation of the partner’s technology. It’s ...
Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist. Biogen described C5aR1 as a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Charles Weissmann's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results